|Assessment Status||Rapid Review Complete|
|Brand||NovoRapid® FlexTouch ®|
|Indication||For the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.|
|Rapid review commissioned||22/07/2014|
|Rapid review completed||28/08/2014|
|Rapid review outcome||Full pharmacoeconomic assessment recommended at the submitted price.|
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.